

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

DUSA PHARMACEUTICALS INC  
Form SC 13G/A  
February 08, 2007

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
-----

SCHEDULE 13G/A  
(Rule 13d-102)  
-----

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO  
RULES 13d-1(b), (c) AND (d) AND AMENDMENTS  
THERE TO FILED PURSUANT TO 13d-2 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934  
(Amendment No. 1)\*

DUSA Pharmaceuticals, Inc.  
(Name of Issuer)

Common Stock, no par value per share  
(Title of Class of Securities)

266898105  
(CUSIP Number)

December 31, 2006  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this  
Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

(Page 1 of 13 Pages)  
-----

\* The remainder of this cover page shall be filled out for a reporting  
person's initial filing on this form with respect to the subject class of  
securities, and for any subsequent amendment containing information which would  
alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be  
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange  
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of  
the Act but shall be subject to all other provisions of the Act (however, see  
the Notes).

Schedule 13G/A  
CUSIP No. 266898105

PAGE 2 of 13

- (1) NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Phaeton International (BVI) Ltd.  
None  
-----

- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

(a) [ ]  
(b) [X]

-----  
(3) SEC USE ONLY  
-----

-----  
(4) CITIZENSHIP OR PLACE OF ORGANIZATION  
British Virgin Islands  
-----

NUMBER OF (5) SOLE VOTING POWER  
SHARES 0  
-----

BENEFICIALLY (6) SHARED VOTING POWER  
OWNED BY 419,600  
-----

EACH (7) SOLE DISPOSITIVE POWER  
REPORTING 0  
-----

PERSON WITH (8) SHARED DISPOSITIVE POWER  
419,600  
-----

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED  
BY EACH REPORTING PERSON  
419,600  
-----

(10) CHECK BOX IF THE AGGREGATE AMOUNT  
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]  
-----

(11) PERCENT OF CLASS REPRESENTED  
BY AMOUNT IN ROW (9)  
2.15%  
-----

(12) TYPE OF REPORTING PERSON  
CO  
-----

Schedule 13G/A  
CUSIP No. 266898105

PAGE 3 of 13

(1) NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Phoenix Partners, L.P.  
13-6272912  
-----

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a) [ ]  
(b) [X]  
-----

(3) SEC USE ONLY  
-----

-----  
(4) CITIZENSHIP OR PLACE OF ORGANIZATION  
New York  
-----

NUMBER OF (5) SOLE VOTING POWER

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

0  
SHARES -----  
BENEFICIALLY (6) SHARED VOTING POWER  
423,400  
OWNED BY -----  
EACH (7) SOLE DISPOSITIVE POWER  
0  
REPORTING -----  
PERSON WITH (8) SHARED DISPOSITIVE POWER  
423,400  
-----  
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED  
BY EACH REPORTING PERSON  
423,400  
-----  
(10) CHECK BOX IF THE AGGREGATE AMOUNT  
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]  
-----  
(11) PERCENT OF CLASS REPRESENTED  
BY AMOUNT IN ROW (9)  
2.17%  
-----  
(12) TYPE OF REPORTING PERSON  
PN  
-----

Schedule 13G/A  
CUSIP No. 266898105

PAGE 4 of 13

(1) NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Phoenix Partners II, L.P.  
84-1631449  
-----  
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a) [ ]  
(b) [X]  
-----  
(3) SEC USE ONLY  
-----  
(4) CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware  
-----

NUMBER OF (5) SOLE VOTING POWER  
0  
SHARES -----  
BENEFICIALLY (6) SHARED VOTING POWER  
101,000  
OWNED BY -----  
EACH (7) SOLE DISPOSITIVE POWER  
0  
REPORTING -----

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

PERSON WITH (8) SHARED DISPOSITIVE POWER  
101,000

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED  
BY EACH REPORTING PERSON  
101,000

(10) CHECK BOX IF THE AGGREGATE AMOUNT  
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]

(11) PERCENT OF CLASS REPRESENTED  
BY AMOUNT IN ROW (9)  
0.52%

(12) TYPE OF REPORTING PERSON  
PN

Schedule 13G/A  
CUSIP No. 266898105

PAGE 5 of 13

(1) NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Phoenix Partners III, L.P.  
32-0145065

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a) [ ]  
(b) [X]

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION  
Delaware

NUMBER OF (5) SOLE VOTING POWER  
SHARES 0

BENEFICIALLY (6) SHARED VOTING POWER  
OWNED BY 18,600

EACH (7) SOLE DISPOSITIVE POWER  
REPORTING 0

PERSON WITH (8) SHARED DISPOSITIVE POWER  
18,600

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED  
BY EACH REPORTING PERSON  
18,600

(10) CHECK BOX IF THE AGGREGATE AMOUNT  
IN ROW (9) EXCLUDES CERTAIN SHARES [ ]

(11) PERCENT OF CLASS REPRESENTED

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

BY AMOUNT IN ROW (9)  
0.1%

-----  
(12) TYPE OF REPORTING PERSON  
PN  
-----

Schedule 13G/A  
CUSIP No. 266898105

PAGE 6 of 13

-----  
(1) NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Morgens, Waterfall, Vintiadis & Co., Inc.  
13-2674766  
-----

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
  
(a)   
(b)

-----  
(3) SEC USE ONLY  
-----

-----  
(4) CITIZENSHIP OR PLACE OF ORGANIZATION  
New York  
-----

NUMBER OF (5) SOLE VOTING POWER  
0  
SHARES -----

BENEFICIALLY (6) SHARED VOTING POWER  
962,600  
OWNED BY -----

EACH (7) SOLE DISPOSITIVE POWER  
0  
REPORTING -----

PERSON WITH (8) SHARED DISPOSITIVE POWER  
962,600  
-----

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
962,600  
-----

(10) CHECK BOX IF THE AGGREGATE AMOUNT  
IN ROW (9) EXCLUDES CERTAIN SHARES

-----  
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
4.94%  
-----

(12) TYPE OF REPORTING PERSON  
IA  
-----

Schedule 13G/A  
CUSIP No. 266898105

PAGE 7 of 13

(1) NAME OF REPORTING PERSON

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
Edwin H. Morgens

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a)   
(b)

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION  
United States

NUMBER OF (5) SOLE VOTING POWER  
SHARES 6,000

BENEFICIALLY (6) SHARED VOTING POWER  
OWNED BY 962,600

EACH (7) SOLE DISPOSITIVE POWER  
REPORTING 6,000

PERSON WITH (8) SHARED DISPOSITIVE POWER  
962,600

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
968,600

(10) CHECK BOX IF THE AGGREGATE AMOUNT  
IN ROW (9) EXCLUDES CERTAIN SHARES

(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
4.97%

(12) TYPE OF REPORTING PERSON  
IN

Schedule 13G/A  
CUSIP No. 266898105

PAGE 8 of 13

(1) NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  
John C. Waterfall

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(a)   
(b)

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION  
United States

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

NUMBER OF	(5)	SOLE VOTING POWER	
SHARES		0	
-----			
BENEFICIALLY	(6)	SHARED VOTING POWER	
OWNED BY		962,600	
-----			
EACH	(7)	SOLE DISPOSITIVE POWER	
REPORTING		0	
-----			
PERSON WITH	(8)	SHARED DISPOSITIVE POWER	
		962,600	
-----			
	(9)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
		962,600	
-----			
	(10)	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	[ ]
-----			
	(11)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	
		4.94%	
-----			
	(12)	TYPE OF REPORTING PERSON IN	
-----			

Schedule 13G/A  
CUSIP No. 266898105

PAGE 9 of 13

- ITEM 1(a). NAME OF ISSUER:  
DUSA Pharmaceuticals, Inc. (the "Company")
- ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:  
25 Upton Drive, Wilmington, MA 01887
- ITEM 2(a). NAME OF PERSON FILING:  
This Schedule 13G is filed jointly by (a) Phaeton International (BVI) Ltd. ("Phaeton"), (b) Phoenix Partners, L.P. ("Phoenix"), (c) Phoenix Partners II, L.P. ("Phoenix II"), (d) Phoenix Partners III, L.P. ("Phoenix III"), (e) Morgens, Waterfall, Vintiadis & Company, Inc. ("Morgens Waterfall" (f) Edwin H. Morgens ("Morgens") and (g) John C. Waterfall ("Waterfall" and together with the persons listed in (a) through (f), the "Reporting Persons").
- Phaeton, Phoenix, Phoenix II and Phoenix III are hereinafter sometimes collectively referred to as the "Advisory Clients".
- ITEM 2(b). ADDRESS OF PRINCIPAL OFFICE OR, IF NONE, RESIDENCE:  
The business address of each of the Reporting Persons is 600 Fifth Avenue, 27th Floor, New York NY 10020.
- ITEM 2(c). CITIZENSHIP:  
Phoenix is a limited partnership organized under the laws of the State of New York. Phoenix II is a limited partnership organized under the laws of the State of Delaware. Phoenix III is a limited

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

partnership organized under the laws of the State of Delaware. Phaeton is an exempted company organized in British Virgin Islands. Morgens Waterfall is a corporation organized under the laws of the State of New York. Each of Morgens and Waterfall are United States citizens.

ITEM 2(d). TITLE OF CLASS OF SECURITIES:  
Common Stock, no par value per share

ITEM 2(e). CUSIP NUMBER:  
266898105.

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

- (a)  Broker or dealer registered under Section 15 of the Act
- (b)  Bank as defined in Section 3(a)(6) of the Act
- (c)  Insurance Company as defined in Section 3(a)(19) of the Act
- (d)  Investment Company registered under Section 8 of the Investment Company Act of 1940
- (e)  Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E)

Schedule 13G/A  
CUSIP No. 266898105

PAGE 10 of 13

- (f)  Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
- (g)  Parent Holding Company, in accordance with Rule 13d-1(b)(ii)(G);
- (h)  Savings Associations as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i)  Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940;
- (j)  Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

IF THIS STATEMENT IS FILED PURSUANT TO Rule 13d-1(c),  
CHECK THIS BOX.

ITEM 4. OWNERSHIP.

The percentages used herein are calculated based on the shares issued and outstanding as of November 3, 2006, as reported in the Company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission by the Company for the quarterly period ending September 30, 2006.

- A. Phaeton International (BVI) Ltd
  - (a) Amount beneficially owned: 419,600
  - (b) Percent of class: 2.1%



Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

- (c) (i) Sole power to vote or direct the vote: -0-
- (ii) Shared power to vote or direct the vote: 419,600
- (iii) Sole power to dispose or direct the disposition: -0-
- (iv) Shared power to dispose or direct the disposition: 419,600

B. Phoenix Partners, L.P.

- (a) Amount beneficially owned: 423,400
- (b) Percent of class: 2.2%
- (c) (i) Sole power to vote or direct the vote: -0-
- (ii) Shared power to vote or direct the vote: 423,400
- (iii) Sole power to dispose or direct the disposition: -0-
- (iv) Shared power to dispose or direct the disposition: 423,400

C. Phoenix Partners II, L.P.

- (a) Amount beneficially owned: 101,000
- (b) Percent of class: 0.6%
- (c) (i) Sole power to vote or direct the vote: -0-
- (ii) Shared power to vote or direct the vote: 101,000
- (iii) Sole power to dispose or direct the disposition: -0-
- (iv) Shared power to dispose or direct the disposition: 101,000

Schedule 13G/A  
CUSIP No. 266898105

PAGE 11 of 13

D. Phoenix Partners III, L.P.

- (a) Amount beneficially owned: 18,600
- (b) Percent of class: 0.1%
- (c) (i) Sole power to vote or direct the vote: -0-
- (ii) Shared power to vote or direct the vote: 18,600
- (iii) Sole power to dispose or direct the disposition: -0-
- (iv) Shared power to dispose or direct the disposition: 18,600

E. Morgens, Waterfall, Vintiadis & Co., Inc.

- (a) Amount beneficially owned: 962,600
- (b) Percent of class: 4.94
- (c) (i) Sole power to vote or direct the vote: -0-
- (ii) Shared power to vote or direct the vote: 962,600
- (iii) Sole power to dispose or direct the disposition: -0-
- (iv) Shared power to dispose or direct the disposition: 962,600

F. Edwin H. Morgens

- (a) Amount beneficially owned: 968,600
- (b) Percent of class: 4.97
- (c) (i) Sole power to vote or direct the vote: 6,000
- (ii) Shared power to vote or direct the vote: 968,600
- (iii) Sole power to dispose or direct the disposition: 6,000
- (iv) Shared power to dispose or direct the disposition: 962,600

G. John C. Waterfall

- (a) Amount beneficially owned: 962,600
- (b) Percent of class: 4.94
- (c) (i) Sole power to vote or direct the vote: -0-
- (ii) Shared power to vote or direct the vote: 962,600

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

- (iii) Sole power to dispose or direct the disposition: -0-
- (iv) Shared power to dispose or direct the disposition:  
962,600

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [x].

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Morgens Waterfall is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, as amended. The business of Morgens Waterfall is the rendering of financial services and as such it provides discretionary investment advisory services to each of the Advisory Clients. In such capacity, Morgens Waterfall has the power to make decisions regarding the dispositions of the proceeds from the sale of the foregoing shares of Common Stock. Under the rules promulgated by the Securities and Exchange Commission, Morgens Waterfall and its principals (Morgens and Waterfall) may be considered "beneficial owners" of securities acquired by the

Schedule 13G/A  
CUSIP No. 266898105

PAGE 12 of 13

Advisory Clients. Each such Advisory Client has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities held in such person's account.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

Not applicable.

ITEM 10. CERTIFICATION. (if filing pursuant to Rule 13d-1(c))

By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Schedule 13G/A  
CUSIP No. 266898105

PAGE 13 of 13

SIGNATURE

After reasonable inquiry and to the best of our knowledge and belief, the

Edgar Filing: DUSA PHARMACEUTICALS INC - Form SC 13G/A

undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: February 7, 2007

-----  
Edwin H. Morgens,  
as attorney-in-fact for  
the Reporting Persons